Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Hedgehog (Hh) signaling is involved in the pathogenesis of liver fibrosis. It has been previously shown that Hh-inhibitor cyclopamine (CYA) can reduce liver fibrosis in rats. However, CYA is not stable in vivo, which limits its clinical application. This study compares the antifibrotic potential of two known Hh antagonists, vismodegib (GDC-0449, abbreviated to GDC) and CYA. GDC is a synthetic molecule presently in clinical cancer trials and has been reported to be safe and efficacious. These drugs attenuated early liver fibrosis in common bile duct ligated rats, improved liver function, and prevented hepatic stellate cell (HSC) activation, thereby suppressing epithelial to mesenchymal transition (EMT). While both CYA and GDC increased the number of proliferating cell nuclear antigen positive liver cells in vivo, only CYA increased Caspase-3 expression in HSCs in rat livers, suggesting that while GDC and CYA effectively attenuate early liver fibrosis, their hepatoprotective effects may be mediated through different modes of action. Thus, GDC has the potential to serve as a new therapeutic agent for treating early liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Role for Hedgehog Signaling in Hepatic Stellate Cell Activation and Viability
Sicklick, J. K., Li, Y.-X., Choi, S. S., Qi, Y., Chen, W., Bustamante, M., Huang, J., Zdanowicz, M., Camp, T., Torbenson, M. S., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700349 · Cited by 179 · cited 1×
“Upon injury-mediated activation, HSCs acquire a myofibroblastic phenotype and produce excessive amounts of ECM, including type I collagen (Friedman, 2008; Sicklick et al., 2005).”
Background
Cited by
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Mia, M. M., Boersema, M., & Bank, R. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091559 · Cited by 109
“Pharmacological inhibition of the SHH pathway results in an attenuation of fibrosis in a variety of in vivo models, namely unilateral ureteral obstruction (UUO) [67], systemic sclerosis [68] and liver cirrhosis [66,69,70], although others did not report improvements [71,72].”
BackgroundDevelopmental Morphogens & Recovery from Alcoholic Liver Disease
Diehl, A. M. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-98788-0_11 · Cited by 5
Metadata
- Authors
- Pratap, A., Singh, S., Mundra, V., Yang, N., Panakanti, R., Eason, J. D., & Mahato, R. I.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2012-09-20
- Volume
- 20
- Issue
- 9
- Pages
- 770-782
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2090930344
- Cited by
- 43
- References
- 2
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. https://app.cochat.ai/papers/10.3109/1061186x.2012.719900
- The paper
- Pratap, A., Singh, S., Mundra, V., Yang, N., Panakanti, R., Eason, J. D., & Mahato, R. I. (2012). Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. Journal of Drug Targeting. https://doi.org/10.3109/1061186x.2012.719900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.